Literature DB >> 24406926

What's fueling the biotech engine-2012 to 2013.

Rob Saurabh Aggarwal1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24406926     DOI： 10.1038/nbt.2794

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  16 in total

1.  Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.

Authors:  Christopher E M Griffiths; Bruce E Strober; Peter van de Kerkhof; Vincent Ho; Roseanne Fidelus-Gort; Newman Yeilding; Cynthia Guzzo; Yichuan Xia; Bei Zhou; Shu Li; Lisa T Dooley; Neil H Goldstein; Alan Menter
Journal:  N Engl J Med       Date:  2010-01-14       Impact factor: 91.245

2.  What's fueling the biotech engine?

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2007-10       Impact factor: 54.908

3.  What's fueling the biotech engine-2011 to 2012.

Authors:  Saurabh Rob Aggarwal
Journal:  Nat Biotechnol       Date:  2012-12       Impact factor: 54.908

4.  Failure to launch.

Authors: 
Journal:  Nat Biotechnol       Date:  2013-01       Impact factor: 54.908

5.  Anthrax drug first antibacterial mAb to win approval.

Authors:  Jeffrey L Fox
Journal:  Nat Biotechnol       Date:  2013-01       Impact factor: 54.908

6.  Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.

Authors:  Chris Fellner
Journal:  P T       Date:  2012-09

7.  Building a wall against biosimilars.

Authors: 
Journal:  Nat Biotechnol       Date:  2013-04       Impact factor: 54.908

8.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Authors: 
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113

9.  Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy.

Authors:  Constantin Volovat; Oleg A Gladkov; Igor M Bondarenko; Steve Barash; Anton Buchner; Peter Bias; Liat Adar; Noa Avisar
Journal:  Clin Breast Cancer       Date:  2013-10-25       Impact factor: 3.225

10.  Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

Authors:  Cem Gabay; Paul Emery; Ronald van Vollenhoven; Ara Dikranian; Rieke Alten; Karel Pavelka; Micki Klearman; David Musselman; Sunil Agarwal; Jennifer Green; Arthur Kavanaugh
Journal:  Lancet       Date:  2013-03-18       Impact factor: 79.321
View more
  56 in total

1.  Monoclonal Antibodies Follow Distinct Aggregation Pathways During Production-Relevant Acidic Incubation and Neutralization.

Authors:  Thomas Skamris; Xinsheng Tian; Matthias Thorolfsson; Hanne Sophie Karkov; Hanne B Rasmussen; Annette E Langkilde; Bente Vestergaard
Journal:  Pharm Res       Date:  2015-11-12       Impact factor: 4.200

2.  Weak protein interactions and pH- and temperature-dependent aggregation of human Fc1.

Authors:  Haixia Wu; Kristopher Truncali; Julie Ritchie; Rachel Kroe-Barrett; Sanjaya Singh; Anne S Robinson; Christopher J Roberts
Journal:  MAbs       Date:  2015-08-12       Impact factor: 5.857

3.  Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab.

Authors:  Fabienne Courtois; Neeraj J Agrawal; Timothy M Lauer; Bernhardt L Trout
Journal:  MAbs       Date:  2016       Impact factor: 5.857

Review 4.  Are BiTEs the "missing link" in cancer therapy?

Authors:  Carter M Suryadevara; Patrick C Gedeon; Luis Sanchez-Perez; Terence Verla; Christopher Alvarez-Breckenridge; Bryan D Choi; Peter E Fecci; John H Sampson
Journal:  Oncoimmunology       Date:  2015-04-30       Impact factor: 8.110

5.  Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.

Authors:  Hongliang Zhao; Deeptak Verma; Wen Li; Yoonjoo Choi; Christian Ndong; Steven N Fiering; Chris Bailey-Kellogg; Karl E Griswold
Journal:  Chem Biol       Date:  2015-05-21

6.  Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics.

Authors:  Richard S Rogers; Nancy S Nightlinger; Brittney Livingston; Phil Campbell; Robert Bailey; Alain Balland
Journal:  MAbs       Date:  2015-07-17       Impact factor: 5.857

7.  Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody.

Authors:  John P Giddens; Joseph V Lomino; David J DiLillo; Jeffrey V Ravetch; Lai-Xi Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-05       Impact factor: 11.205

Review 8.  Polymeric nanoparticle drug delivery technologies for oral delivery applications.

Authors:  Eric M Pridgen; Frank Alexis; Omid C Farokhzad
Journal:  Expert Opin Drug Deliv       Date:  2015-03-26       Impact factor: 6.648

9.  Automated pipeline for rapid production and screening of HIV-specific monoclonal antibodies using pichia pastoris.

Authors:  Kartik A Shah; John J Clark; Brittany A Goods; Timothy J Politano; Nicholas J Mozdzierz; Ross M Zimnisky; Rachel L Leeson; J Christopher Love; Kerry R Love
Journal:  Biotechnol Bioeng       Date:  2015-07-31       Impact factor: 4.530

10.  Technological advances in precision medicine and drug development.

Authors:  Elaine Maggi; Nicole E Patterson; Cristina Montagna
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.